Advertisement

September 14, 2020

Prediction Model Developed for Patient Outcomes With Cook Medical’s Zilver PTX DES

September 14, 2020—Cook Medical announced that a prediction model for treatment outcomes with the company’s Zilver PTX paclitaxel-coated drug-eluting stent (DES) was presented by Michael Dake, MD, at the Cardiovascular and Interventional Radiological Society of Europe’s CIRSE 2020 Summit held online September 12-15.

According to Cook Medical, the model provides increased transparency regarding the effects that patients and physicians can expect when using Zilver PTX.

Dr. Dake worked with Cook Research, Inc. to create this prediction model to determine the impact of patient and lesion factors on freedom from target lesion revascularization (TLR) for patients who are candidates for Zilver PTX treatment. Dr. Dake is the Senior Vice President of Health Sciences at the University of Arizona in Tucson, Arizona, and is President-Elect of the Society of Interventional Radiology’s Executive Council.

The company stated that the prediction model was developed by compiling patient factors, lesion characteristics, and total TLR rates from five global studies of the Zilver PTX clinical program. Based on the data from the five studies of more than 2,200 patients, the model takes into account 15 patient factors, including sex, age, lesion length, the severity of calcification, diabetes, and previous interventions.

The prediction model that Dr. Dake presented at the CIRSE 2020 Summit has been accepted for publication in CardioVascular and Interventional Radiology, advised the company.

“We are sharing this prediction model and its associated outcomes to continue being transparent with data,” commented Mark Breedlove, Vice President of Cook Medical’s vascular division, in the company's announcement. “We hope patients and physicians can use this model to be more informed about Zilver PTX in choosing the best treatment option. This prediction model allows clinicians and patients to have better conversations around expected outcomes with Zilver PTX.”

Advertisement


September 14, 2020

FUTURE SFA Trial of Concept Medical’s MagicTouch Sirolimus-Coated Balloon Commences Enrollment

September 11, 2020

FDA Clears Avinger’s Next-Gen Ocelaris CTO Crossing System, to Be Marketed as Tigereye